---
layout: default
title: Zinc Chloride
parent: Model Prediction Only (L5)
nav_order: 905
evidence_level: L5
indication_count: 3
last_modified_at: 2026-10-14
description: "Zinc Chloride: predicted new indication Severe nonproliferative diabetic retinopathy (evidence level L5). Approved use: Not recorded"
---

# Zinc Chloride
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **3** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Zinc Chloride: From an Unspecified Original Indication to Severe Nonproliferative Diabetic Retinopathy

## One-Sentence Summary

Zinc chloride is marketed in India as an injectable (Zincshot Injection), but the data compiled for this report do not record an approved indication.
The TxGNN model predicts it may be effective for **severe nonproliferative diabetic retinopathy**, and also ranks **Sjogren syndrome** and **dry eye syndrome** highly.
Currently there are **0 clinical trials** and **0 publications** supporting any of these predictions, so this is a computational prediction only.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not recorded (the approved indication text on the India license is empty) |
| Predicted New Indication | Severe nonproliferative diabetic retinopathy |
| TxGNN Prediction Score | 99.34% |
| Evidence Level | L5 |
| India Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |

Other predicted indications:

| Rank | Predicted Indication | TxGNN Score | Evidence Level | Decision |
|------|------|------|------|------|
| 2 | Sjogren syndrome | 99.18% | L5 | Hold |
| 3 | Dry eye syndrome | 99.18% | L5 | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Zinc chloride is a zinc salt supplied as an injectable product in India. Because no approved indication is recorded, the relationship between its original use and the new indication cannot be assessed.

A plausible but untested link exists through zinc's biology. Zinc is a cofactor for antioxidant enzymes such as Cu/Zn superoxide dismutase, which may bear on oxidative stress and retinal microvascular damage in diabetes. This is a hypothesis only and is not supported by any trial or publication in the data compiled for this report.

For the other two predictions, zinc is involved in immune regulation and epithelial integrity (relevant to Sjogren syndrome), and in ocular surface maintenance, wound healing, and anti-inflammatory activity (relevant to dry eye syndrome). These rationales are also speculative. The high TxGNN scores (about 99%) reflect model output, not clinical proof.

## India Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| 247261 | Zincshot Injection (Fusion Healthcare Pvt Ltd) | Vial of 10 ml injection | Not recorded |

The only available route is injectable. Whether this is compatible with the route needed for the predicted eye or exocrine-gland indications has not been assessed.

## Safety Considerations

- **Disease-level contraindication signals (knowledge graph, not label text):** The TxGNN knowledge graph links zinc chloride to contraindications in methemoglobinemia, sulfhemoglobinemia, G6PD deficiency, glycogen storage disease, cystinuria, galactosemia, pyruvate dehydrogenase E3 deficiency, methemoglobin reductase deficiency, Wilson disease, iron metabolism disease, and hereditary hemochromatosis. These come from graph edges and should be verified against the product label.
- **Drug Interactions:** 76 interactions are recorded. Most of those listed are Minor, including corticosteroids (hydrocortisone, prednisone, prednisolone, dexamethasone, betamethasone, budesonide, triamcinolone) and several immunosuppressants and biologics (e.g., abatacept, adalimumab, azathioprine, anakinra, baricitinib). Moderate interactions include **tetracycline, minocycline, and levofloxacin**, where zinc may reduce antibiotic absorption. Spacing the doses is a common precaution, but this should be confirmed.

Please refer to the package insert for warnings and contraindications, which are not available in the data compiled for this report.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
All three predictions rest on model scores alone (L5), with no registered clinical trials or publications. The original indication and mechanism of action are not recorded, and the package insert safety information is missing, which blocks safety screening.

**To proceed, the following is needed:**
- Obtain and parse the package insert for Zincshot Injection (approved indication, warnings, contraindications)
- Obtain mechanism of action data (e.g., from DrugBank)
- Search for clinical and preclinical evidence on zinc in diabetic retinopathy, Sjogren syndrome, and dry eye
- Assess route compatibility, since the marketed product is an injection and the predicted indications may need topical or oral delivery
- Review the knowledge-graph contraindications (especially Wilson disease, hemochromatosis, G6PD deficiency) against the label
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

